10.01.2021 | Gynecologic Oncology
Multidisciplinary Surgical Approach to Increase Complete Cytoreduction Rates for Advanced Ovarian Cancer in a Tertiary Gynecologic Oncology Center
verfasst von:
Karen M. Mulligan, MA Genetics, MD, Kate Glennon, MD, MRCPI, Fionán Donohoe, MD, MRCPI, MRCOG, Yvonne O’Brien, MD, MRCPI, MRCOG, Brian C. Mc Donnell, MD, Helena C. Bartels, MD, MRCPI, Carolien Vermeulen, MB, BCh, Tom Walsh, MD, MRCPI, MRCOG, Conor Shields, BSc, MD, FRCSI, Orla McCormack, MD, FRCSI, John Conneely, MD, BSc, MCh, FRCSI (Gen), William D. Boyd, MD, MRCOG, FRC, ONC, CAN, Ruaidhrí Mc Vey, LRCP&SI (Hons), MRCSI, MRCPI, MRCOG, MD, MCE, MSc, Jurgen Mulsow, MB, MD, FRCSI, Donal J. Brennan, MD, MRCPI, MRCOG, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2021
Einloggen, um Zugang zu erhalten
Abstract
Background
Surgical resection remains the cornerstone of ovarian cancer management. In 2017, the authors implemented a multi-disciplinary surgical team comprising gynecologic oncologists as well as colorectal, hepatobiliary, and upper gastrointestinal (GI) surgeons to increase gross macroscopic resection rates. This report aims to describe changes in complete cytoreduction rates and morbidity after the implementation of a multi-disciplinary surgical team comprising gynecologic oncologists as well as colorectal, hepatobiliary, and upper GI surgeons in a tertiary gynecologic oncology unit.
Methods
The study used two cohorts. Cohort A was a retrospectively collated cohort from 2006 to 2015. Cohort B was a prospectively collated cohort of patients initiated in 2017. A multidisciplinary approach to preoperative medical optimization, intraoperative management, and postoperative care was implemented in 2017. The patients in cohort B with upper abdominal disease were offered primary cytoreduction with or without hyperthermic intraperitoneal chemotherapy (HIPEC). Before 2017, the patients with upper abdominal disease received neoadjuvant chemotherapy (cohort A).
Results
This study included 146 patients in cohort A (2006–2015) and 93 patients in cohort B (2017–2019) with stages 3 or 4 ovarian cancer. The overall complete macroscopic resection rate (CC0) increased from 58.9 in cohort A to 67.7% in cohort B. The rate of primary cytoreductive surgery (CRS) increased from 38 (55/146) in cohort A to 42% (39/93) in cohort B. The CC0 rate for the patients who underwent primary CRS increased from 49 in cohort A to 77% in cohort B. Major morbidity remained stable throughout both study periods (2006–2019).
Conclusions
The study data demonstrate that implementation of a multidisciplinary team intraoperative approach and a meticulous approach to preoperative optimization resulted in significantly improved complete resection rates, particularly for women offered primary CRS.